280E Tax Burden and IRS Guidance for Cannabis Businesses

Executive Summary

Section 280E of the Internal Revenue Code denies ordinary business deductions to anyone "trafficking" in Schedule I or II controlled substances, and licensed cannabis operators have carried that burden for more than four decades while waiting for federal rescheduling and IRS guidance to change it.

Under 26 U.S.C. § 280E, a cannabis business may subtract only cost of goods sold (COGS) from gross receipts. Rent, payroll for non-production staff, marketing, and other operating expenses are not deductible. The result is an effective federal tax rate that, for many retail-heavy operators, runs far above the 21 percent statutory corporate rate and can exceed 100 percent of net operating income in thin-margin years.

A November 14, 2026 report from The Marijuana Herald said five major marijuana companies disclosed roughly $2 billion in uncertain tax liabilities as IRS guidance on how 280E applies after rescheduling remains pending. Those liabilities, booked under uncertain tax position accounting rules, reflect a simple problem: operators cannot tell whether a move of marijuana to Schedule III would end 280E exposure going forward, and whether it would help for past years at all.

This hub explains the statute, the litigation that shaped it, the rescheduling pathway through the DEA, the competing company positions (including the "we are not trafficking" refund claims), state-level responses, and what operators, investors, and patients should watch. It is written as a standing reference. Dated updates will be added below as the IRS, DEA, Treasury, and courts act.

The central analytical point: rescheduling is necessary but not sufficient for 280E relief. The statute's trigger is the Controlled Substances Act schedule, but timing, retroactivity, mixed-schedule products, and the IRS's own enforcement posture will determine who benefits and when.

Why This Matters

280E is the single largest structural drag on U.S. cannabis profitability, shifting billions of dollars annually from operators, employees, and ultimately patients and consumers to the U.S. Treasury.

The stakes break down across four groups:

• Operators and MSOs. Multi-state operators (MSOs) report cash taxes that routinely exceed book income. Reserve accounts for unpaid or contested 280E amounts have become a defining balance-sheet feature of the sector, which is why the $2 billion uncertain-tax-liability figure drew attention.
• Lenders and investors. Cannabis debt is priced at double-digit yields partly because after-tax cash flow is unpredictable. Any clarity on 280E feeds directly into covenant compliance, refinancing, and equity valuations.
• Small and social-equity operators. Independent licensees in states such as California, Colorado, and Oregon often lack the accounting sophistication to maximize COGS allocation under 26 U.S.C. § 471, and they cannot absorb a tax bill larger than their profit.
• Patients and consumers. Tax costs are priced into shelf prices, which keeps licensed products above illicit-market prices and weakens the case that regulated markets can displace unlicensed sales.

The scale is sector-wide. Industry trade groups have repeatedly estimated that 280E costs the legal cannabis industry several billion dollars per year in aggregate, though no official federal figure is published. What is documented are the individual company disclosures in SEC filings, where uncertain tax positions and accrued 280E liabilities appear as line items.

Background and History

Section 280E was enacted in 1982 as a response to a drug dealer's tax case and has never been amended, even as 40 states legalized medical or adult-use cannabis.

1982: The Origin in Jeffrey Edmondson

The statute traces to Edmondson v. Commissioner (T.C. Memo. 1981-623), in which the Tax Court allowed a convicted drug trafficker to deduct ordinary business expenses such as rent, phone, and car costs from an illegal drug operation. Congress, working within the Tax Equity and Fiscal Responsibility Act of 1982, responded by adding Section 280E. The text disallows "any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted."

1996 to 2012: State Legalization Without Tax Relief

California's Proposition 215 in 1996 launched the medical marijuana era. Over the next decade and a half, states from Oregon to Colorado built regulated dispensary systems. Early dispensary operators generally did not know 280E applied to them, and many filed returns taking ordinary deductions. The IRS began auditing cannabis businesses in the late 2000s.

2007: Californians Helping to Alleviate Medical Problems (CHAMP)

In Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, 128 T.C. 173 (2007), the Tax Court held that a medical marijuana dispensary was trafficking within the meaning of 280E and could not deduct ordinary expenses. The court did, however, recognize that a taxpayer with more than one trade or business could deduct expenses allocable to the non-trafficking business. That recognition produced the "separate business" strategy that operators still test today.

2012 to 2014: Colorado and Washington Launch Adult-Use

Voters in Colorado and Washington legalized adult-use sales in 2012, with sales beginning in 2014. The new adult-use markets multiplied the number of licensed taxpayers affected by 280E, and the IRS stepped up audits focused on COGS allocation.

2015: Harborside and the COGS Fight

In Harborside Health Center v. Commissioner, 151 T.C. 315 (2018), arising from the 2015 audit era, the Tax Court held that Harborside, a large California dispensary, could not allocate substantial overhead to COGS and that its ancillary activities were not a separate business. The court confirmed that resellers may include only costs permitted under 26 U.S.C. § 471, rather than the broader capitalization rules available to producers under § 263A. The case widened the gap between plant-touching producers and retailers, because retailers have far fewer allowable inventory costs.

2018: Alterman and Alpenglow

In Alterman v. Commissioner, T.C. Memo. 2018-83, the court upheld a 280E denial for a dispensary. In Alpenglow Botanicals, LLC v. United States (10th Cir. 2018), the Tenth Circuit held that 280E applied and rejected constitutional arguments that the provision was an unconstitutional tax on illegal income or a violation of the Eighth Amendment. These decisions established that constitutional challenges were unlikely to succeed.

2019 to 2021: Patients Out of Pocket and the Safe Harbor That Wasn't

The Tax Court in Patients Mutual Assistance Collective Corp. v. Commissioner, 151 T.C. 176 (2018), later affirmed by the Ninth Circuit in 2021, held that a dispensary selling both cannabis and non-cannabis items (such as paraphernalia) could not avoid 280E by calling the activities separate when they were commercially intertwined. The ruling reinforced that carving out a non-cannabis business requires real operational separation.

2022: Rescheduling Enters the Mainstream

In October 2022, President Biden directed the Department of Health and Human Services (HHS) and the Attorney General to review marijuana's scheduling under the Controlled Substances Act. This review, rather than legislation, became the likeliest path to 280E relief.

2023: HHS Recommendation

In August 2023, HHS delivered a recommendation to the DEA to move marijuana to Schedule III, based on a finding of currently accepted medical use and lower abuse potential than Schedule I or II substances. Schedule III substances are not within the text of 280E, which names only Schedules I and II.

2024: Proposed Rule and ALJ Hearing Process

In May 2024, the DEA published a notice of proposed rulemaking (NPRM) to transfer marijuana to Schedule III. The agency then moved toward an administrative hearing before an administrative law judge (ALJ), a process that was delayed by procedural disputes over participants and scheduling. The pending hearing and follow-on final rule became the gating events for any 280E change.

2025 and 2026: Executive Action and Company Tax Positions

Through 2025 and into 2026, the rescheduling process remained the central federal cannabis policy question. During this period, several publicly reporting companies began taking aggressive tax positions: filing amended returns or protective refund claims asserting that they are not "trafficking" in the first place, and recording uncertain tax liabilities against the possibility that the IRS prevails. The November 2026 report that five major companies collectively disclosed about $2 billion in uncertain tax liabilities is the latest data point showing how heavily these positions weigh on balance sheets while IRS guidance remains unpublished.

Key Players

The 280E outcome turns on a small set of federal decision-makers, a handful of well-capitalized operators, and trade groups pressing for both rescheduling and tax relief.

The Internal Revenue Service and Treasury

The IRS administers 280E and controls audit, examination, and refund processing. Treasury and the IRS Office of Chief Counsel would issue any guidance on how Schedule III status affects tax years before and after the effective date. As of this writing, the agencies have not published comprehensive guidance, which is the "pending" status the news report highlights. The IRS has historically defended 280E in court and in audits, including challenging refund claims premised on the argument that state-licensed activity is not "trafficking."

The Drug Enforcement Administration

The DEA holds the formal authority to schedule or reschedule controlled substances under the Controlled Substances Act, 21 U.S.C. § 811, with a binding scientific and medical evaluation from HHS. Its NPRM, any ALJ proceedings, and a final rule determine when marijuana leaves Schedules I and II for 280E purposes.

The FDA and HHS

The FDA, acting for HHS, produced the eight-factor analysis supporting Schedule III. Its findings on accepted medical use are legally significant because they undercut the Schedule I definition at 21 U.S.C. § 812(b)(1).

Multi-State Operators

The largest MSOs, including Curaleaf, Green Thumb Industries, Trulieve, Verano, and Cresco Labs, disclose 280E exposure in their public filings. The Marijuana Herald's report involved five major companies' uncertain tax liabilities. MSOs are the most likely beneficiaries of rescheduling and the most aggressive litigants over refund and non-trafficking theories.

Trade Associations and Advocates

The National Cannabis Industry Association, the U.S. Cannabis Council, and state associations lobby both for rescheduling and for statutory fixes. Legislative proposals to amend or carve cannabis out of 280E, including bills in past Congresses to exempt state-compliant businesses, have been introduced repeatedly without becoming law.

Opposition and Skeptics

Some law-enforcement groups and anti-legalization organizations oppose rescheduling. Separately, some tax practitioners caution that treating marijuana as Schedule III does not by itself eliminate the Controlled Substances Act's prohibition on non-FDA-approved distribution, which keeps the "trafficking" characterization alive in some readings.

Legal and Regulatory Framework

The 280E regime rests on four layers: the statute, Treasury regulations and IRS guidance on inventory costs, Tax Court precedent, and the Controlled Substances Act schedules that define the trigger.

The Statute: 26 U.S.C. § 280E

The text reaches only Schedule I and II substances. This is why rescheduling matters: if marijuana becomes Schedule III, the plain language of 280E no longer reaches it on and after the effective date of the move. Whether the denial of deductions for earlier tax years stands, and whether the IRS accepts any pre-rescheduling theory, is a separate question.

Inventory Cost Rules: §§ 471 and 263A

Because 280E does not disturb COGS (a reduction of gross receipts, not a deduction), the allocation of costs to inventory is the key battleground. Producers (cultivators and manufacturers) may use § 263A full absorption costing and capitalize indirect production costs. Resellers (dispensaries) are limited to § 471 costs, generally the invoice price plus transportation. A 2007 Treasury position and subsequent Tax Court rulings, including Harborside, enforce this distinction. Vertically integrated MSOs therefore have more flexibility on the wholesale side than on the retail side.

Controlled Substances Act: 21 U.S.C. §§ 811-812

Marijuana is currently listed in Schedule I at 21 U.S.C. § 812(c). Moving it requires a rulemaking under § 811 after HHS review. Schedule III substances such as certain anabolic steroids and ketamine are lawful when prescribed or distributed under the CSA's registration regime; outside that regime, they are still unlawful to distribute. This is the root of the debate over whether a state-licensed dispensary would remain "trafficking" in a Schedule III substance, even though 280E's text would no longer apply.

Key Case Law

• CHAMP v. Commissioner, 128 T.C. 173 (2007): 280E applies to state-legal medical marijuana dispensaries; separate businesses may deduct their own expenses.
• Harborside Health Center v. Commissioner, 151 T.C. 315 (2018): resellers limited to § 471 costs; separate-business argument rejected on the facts.
• Patients Mutual Assistance Collective Corp. v. Commissioner, 151 T.C. 176 (2018), aff'd (9th Cir. 2021): intertwined activities are one trafficking business.
• Alpenglow Botanicals v. United States (10th Cir. 2018): 280E survives constitutional challenge.

Federalism

State law cannot repeal a federal tax statute. Many states decouple their own income tax from 280E, allowing state-level deductions even where federal deductions are denied. Others conform and apply 280E automatically. This divergence produces very different effective tax burdens depending on where an operator is licensed.

Uncertain Tax Positions: ASC 740

Under accounting standard ASC 740-10 (formerly FIN 48), a company must record a liability for tax positions it is not more than 50 percent likely to sustain on examination. The $2 billion figure in the news report reflects this regime: when a company takes a position such as "we owe no 280E tax" but cannot confirm it will prevail, it reserves the exposure. That is why the pending IRS guidance matters to the balance sheet, not just to the tax return.

State-by-State Breakdown

Because 280E is federal, every state-licensed operator is exposed, but state income tax conformity, excise taxes, and COGS rules produce significant variation in total tax burden.

California

California, the largest legal market, decouples from 280E for state income tax purposes under legislation enacted in 2019, allowing state-level deductions. Operators still face the federal 280E denial and a layered system of cultivation, excise, and local taxes that has contributed to ongoing competition from the unlicensed market.

Colorado

Colorado, with adult-use sales since 2014, allows a state-level deduction for expenses disallowed federally under 280E. The state has a long compliance history and a large population of examined taxpayers, making it a key source of audit experience.

New York

New York's adult-use market launched in late 2022. New York licensees pay federal 280E and navigate state potency-based and sales taxes. The state's large population and new retail footprint make it a priority market for operators watching rescheduling outcomes.

Ohio

Ohio voters approved adult-use legalization in 2023, with sales beginning in 2024. Ohio's newer market structure means many operators are early in their tax-planning cycle and have limited audit history.

Massachusetts

Massachusetts has been among the more mature East Coast markets and has seen significant operator consolidation and price compression, factors that interact with the fixed federal 280E burden on thin margins.

Illinois, Michigan, and Other Mature Markets

Illinois and Michigan, with large adult-use sales, are home to major MSO operations and meaningful 280E accruals. Operators in these states weigh the same trade-offs: federal denial of deductions, state-level tax layers, and wholesale price declines.

Factor	Producer / Cultivator	Retailer / Dispensary
Inventory costing rule	§ 263A full absorption	§ 471 (invoice + freight)
Typical deductible overhead share	Higher	Low
Federal 280E exposure	Moderate to high	Highest
Vertical integration effect	Shifts margin to wholesale where COGS is richer	Retail margin carries least relief

Market and Business Implications

Resolution of 280E would be one of the largest single balance-sheet events in the history of the legal cannabis industry, with effects on cash taxes, debt capacity, M&A, and pricing.

Cash Flow and Valuation

For an MSO paying cash taxes well above book tax expense, eliminating 280E for future periods converts a structural cost into retained cash. Analysts who cover the sector tend to treat 280E relief as a re-rating catalyst, though the size depends on the effective date, the treatment of prior-year liabilities, and any continuing state-level friction.

The Refund Question

The most consequential open issue is whether operators can recover taxes already paid. Several companies have taken the position that they were never subject to 280E because state-licensed cannabis commerce is not "trafficking," and they have filed protective claims. The IRS has not conceded this theory, and courts have not endorsed it. Reserves recorded as uncertain tax liabilities reflect the possibility that those claims fail and that the IRS asserts deficiencies, interest, and penalties for years already filed.

Wholesale Pricing Read

If 280E relief materializes, cultivators and manufacturers are better positioned to absorb it as pure margin, while retailers may face pressure to pass savings to consumers as competition drives shelf prices down. In oversupplied markets such as Oregon and California, where wholesale prices have already fallen sharply, tax savings may be competed away faster than in limited-license states.

Capital Flows and Banking

Rescheduling alone does not make marijuana federally legal, and it does not by itself provide safe banking under federal law. Lenders will watch whether Schedule III status changes the treatment of cannabis deposits and whether FDA registration requirements apply to commercial distribution. Capital markets access for U.S. plant-touching companies remains constrained relative to other regulated industries.

Planning Posture for Operators

• Maintain meticulous COGS documentation under §§ 471 and 263A.
• Evaluate whether a genuinely separate non-cannabis business exists, keeping records that satisfy the CHAMP and Patients Mutual tests.
• Model both rescheduling-with-relief and rescheduling-without-retroactivity scenarios.
• Coordinate uncertain-tax-position reserves with auditors under ASC 740.

What Experts Say

Tax practitioners and analysts broadly agree that rescheduling would end 280E exposure going forward, but they split on retroactivity, on the "not trafficking" refund theory, and on how the IRS will treat the transition.

Based on public commentary from tax attorneys and industry accountants, three positions recur. First, many practitioners hold that because 280E's text names only Schedules I and II, a final rule moving marijuana to Schedule III would remove the statutory trigger from its effective date forward. Second, a more cautious group notes that the Controlled Substances Act would still prohibit distribution outside its registration framework, and that the IRS could argue the activity remains unlawful trafficking in a controlled substance even if the schedule changes; they stress that 280E's text reaches only Schedules I and II, which leaves little room for that argument but does not eliminate litigation risk. Third, practitioners focused on past years emphasize that nothing in rescheduling would automatically reopen closed tax years or grant refunds.

Financial analysts covering the sector, as reflected in the sources behind the November 2026 report, treat the $2 billion in disclosed uncertain tax liabilities as a signal that auditors and management teams do not consider favorable outcomes assured. The disclosure itself is not an admission that the tax is owed; under ASC 740 it reflects a threshold of likelihood, not a concession.

The consistent professional view is that 280E relief depends on three separate events: a final scheduling rule, IRS guidance on transition and enforcement, and resolution of prior-year positions, and only the first is directly in the DEA's hands.

What's Next

The decisive near-term events are a final DEA scheduling action, IRS and Treasury guidance on transition, and the outcome of pending refund and audit disputes.

Decision Points to Watch

1. DEA rulemaking status. Whether the ALJ process concludes and the DEA issues a final rule moving marijuana to Schedule III, and the rule's effective date.
2. IRS guidance. Whether the IRS issues a notice, revenue ruling, or FAQ addressing 280E for periods around the effective date, including treatment of inventory and mixed-schedule operations.
3. Refund claim litigation. Court decisions testing the "not trafficking" theory, which would affect prior-year liabilities for companies carrying large reserves.
4. Congressional action. Any legislation that would amend 280E directly or codify rescheduling.
5. Next earnings cycle. Updated uncertain-tax-position disclosures in quarterly and annual filings, which show how auditors weigh the probabilities.

Scenarios

• Prompt rescheduling with prospective relief only. 280E ends on the effective date; prior-year liabilities and reserves remain in dispute. This is the baseline many practitioners model.
• Rescheduling with IRS transition guidance. Clear rules on inventory, mixed operations, and audit posture reduce uncertainty and may allow reserve releases.
• Continued delay. Pending guidance and an unresolved hearing process leave operators in the current position, with reserves persisting and refund claims aging.
• Adverse refund rulings. Courts reject the non-trafficking theory, prompting reserve increases and potential deficiency assessments.

Updates to this page will be appended below as these events occur.

Further Reading

Primary sources for 280E, rescheduling, and cannabis tax accounting are available directly from Congress, the IRS, the Tax Court, and the DEA.

• 26 U.S.C. § 280E, Expenditures in connection with the illegal sale of drugs: https://www.law.cornell.edu/uscode/text/26/280E
• 26 U.S.C. § 471, General rule for inventories: https://www.law.cornell.edu/uscode/text/26/471
• 26 U.S.C. § 263A, Capitalization and inclusion in inventory costs: https://www.law.cornell.edu/uscode/text/26/263A
• 21 U.S.C. § 811, Authority and criteria for classification of substances: https://www.law.cornell.edu/uscode/text/21/811
• 21 U.S.C. § 812, Schedules of controlled substances: https://www.law.cornell.edu/uscode/text/21/812
• U.S. Tax Court opinions search (CHAMP, Harborside, Patients Mutual): https://www.ustaxcourt.gov/
• DEA Diversion Control Division, Scheduling actions: https://www.deadiversion.usdoj.gov/
• Federal Register, DEA marijuana rescheduling notice of proposed rulemaking: https://www.federalregister.gov/
• IRS home page and guidance search: https://www.irs.gov/
• Triggering report, The Marijuana Herald (via Google News), November 14, 2026: https://news.google.com/rss/articles/CBMi4gFBVV95cUxPOUpMYjJWTERKOVJtZHQzX2QzVWtsTWZtYlhwTzFSZXktZXZxOXpXajdVdEwxOEJSR2diemZDbEVDRC00SEZOX2FsREZjQkRXOEJsWGRVX1Z2NG4zZDVOUTV6cFlWbjFrTDZoekdCQU1WbFM2d0FhcHJKY2RyY2daN0ttZDBqTlBJVHJjRmdDTm5GT0xUWUhrQi0xUlFOMU51VndCX211el96NEtxbVZCQmJ2U3I0c1RKSkhDWUdGQk9ZYVg5Ni1TcXptaDBtclZ1VFFoMjlYajhCWTJwOTVTdjZn?oc=5